Repligen Expands Manufacturing Facility for Biologic Consumables
Repligen Corporation, a manufacturer of consumables for biomanufacturing, is expanding its manufacturing facility in Waltham, Massachusetts. The company has begun construction of a 7,500-square-foot manufacturing facility expansion designed primarily for alternate tangent flow (ATF) system assembly. The ATF system is a filtration device intended to increase product yields during fermentation. The company provided an update of the project as part of its third-quarter earning release.
Repligen gained the ATF system from its acquisition of Pine Brook, New-Jersey-based Refine Technology in June 2014. By continuously removing waste products from the fermentor, the ATF system is designed to increase cell densities compared to those offered by standard batch fermentation. As a result, product yield is increased, which can reduce the size of a bioreactor required to manufacture a given volume of biologic drug product. The ATF System is available in a range of sizes from laboratory scale to commercial manufacturing. At the time of its acquisiion of Refine Technology in June 2014, Repligen said it planned to develop a single-use, consumable version of the ATF system for single-use bioreactors.
The company expects to transition all ATF system operations from Pine Brook, New Jersey, to its Waltham headquarters by the end of 2014. In addition to Waltham, the company has manufacturing facilities in Lund, Sweden.
Source: Repligen